| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,480 | 0,730 | 07:00 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.04. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 08.04.2026 | 470 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 08.04.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 08.04.2026ISIN NameCA09173B1076 BITFARMS... ► Artikel lesen | |
| 02.03. | Anebulo Pharmaceuticals, Inc. - 15-12G, Securities registration termination | 1 | SEC Filings | ||
| 12.02. | Anebulo Pharmaceuticals GAAP EPS of -$0.05 | 3 | Seeking Alpha | ||
| 12.02. | Anebulo Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.02. | Anebulo Pharmaceuticals: Aktie bricht nach Ankündigung des NASDAQ-Delistings ein | 1 | Investing.com Deutsch | ||
| ANEBULO PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 06.02. | Anebulo Pharmaceuticals plant Delisting von der Nasdaq und Deregistrierung bei der SEC | 1 | Investing.com Deutsch | ||
| 06.02. | Anebulo Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.02. | Anebulo Pharmaceuticals to delist from Nasdaq, deregister with SEC | 1 | Investing.com | ||
| 06.02. | Anebulo Pharmaceuticals, Inc. Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC | 280 | Business Wire | AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic... ► Artikel lesen | |
| 27.01. | Anebulo Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.01. | Anebulo schließt stark überzeichnetes Aktienrückkaufangebot ab | 7 | Investing.com Deutsch | ||
| 27.01. | Anebulo completes oversubscribed share repurchase tender offer | 2 | Investing.com | ||
| 22.12.25 | Anebulo Pharmaceuticals verwirft Reverse Split - Aktie stürzt ab | 7 | Investing.com Deutsch | ||
| 22.12.25 | Anebulo shifts from reverse stock split to tender offer in go-private plan | 10 | Investing.com | ||
| 22.12.25 | Anebulo Pharmaceuticals, Inc. Announces Its Intent to Commence a Self Tender Offer | 189 | Business Wire | AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic... ► Artikel lesen | |
| 22.12.25 | Anebulo Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Anebulo Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 23.07.25 | XFRA 214: WIEDERAUFNAHME/RESUMPTION | 345 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 23.07.25 | Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock | 221 | Business Wire | AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic... ► Artikel lesen | |
| 23.07.25 | XFRA 214: AUSSETZUNG/SUSPENSION | 325 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILANEBULO PHARMAC.... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 87,50 | +0,98 % | BioNTech: Gute News - doch reicht das? | Nach dem heftigen Rücksetzer bei BioNTech, nachdem bekannt wurde, dass die beiden Gründer Ugur Sahin und Özlem Türeci bis spätestens Ende des Jahres das Unternehmen verlassen werden, arbeitet die Aktie... ► Artikel lesen | |
| EVOTEC | 5,590 | +0,36 % | Aktien KW 15 Trump hält die Börsen im Griff. Wacklige Waffenruhe bringt Erholung, aber… News. Mutares. Evotec. TKMS. technotrans. HENSOLDT. Renk. Circus. Albis Leasing. Rheinmetall | Aktien - Erholungsaufatmer nach Waffenstillstand. Mit apokalyptischen Drohungen malte Trump die "Steinzeit" für den Iran an die Wand. Unter Vermittlung Pakistans - auch Chinas? - gab es kurz vorher... ► Artikel lesen | |
| MODERNA | 46,810 | +0,83 % | Moderna - MRNA: Impfstoff-Aktie mit mega-starkem Comeback! | + 100 Prozent in 6 Monaten! mrRNA-Impfstoffe gegen Krebs, Grippe & RSV bei Moderna in der Pipeline! Neue Rallye trotz US-Gesundheitsminister Robert F. Kennedy? Moderna (MRNA) - ISIN US60770K1079 Rückblick:... ► Artikel lesen | |
| AMGEN | 295,80 | -0,24 % | $1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today | ||
| STRYKER | 285,90 | -0,49 % | Stryker To Buy Amplitude Vascular Systems | WASHINGTON (dpa-AFX) - Stryker Corporation (SYK), a medical technology company, said on Monday that it has signed a deal to buy Amplitude Vascular Systems, Inc., a privately held developer of... ► Artikel lesen | |
| BIOGEN | 150,08 | +0,47 % | Piper Sandler upgrades Biogen stock rating on acquisition strength | ||
| CRISPR THERAPEUTICS | 47,980 | +1,50 % | 2 Billion Reasons to Love CRISPR Therapeutics Right Now | ||
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| OCUGEN | 1,652 | +0,61 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,981 | +0,05 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,600 | +1,49 % | Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026? | ||
| MAINZ BIOMED | 0,504 | 0,00 % | MAINZ BIOMED N.V. - 8-K, Current Report | ||
| EDITAS MEDICINE | 2,840 | -0,35 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| ABIVAX | 105,30 | +2,23 % | EQS-News: ABIVAX: Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies | EQS-News: ABIVAX
/ Key word(s): Miscellaneous
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
01.04.2026 / 22:05 CET/CEST
The... ► Artikel lesen |